Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
19 12월 2022 - 8:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced
positive coverage decisions from four private payers including Blue
Cross Blue Shield of North Carolina, Blue Cross Blue Shield of
South Carolina, Blue Cross Blue Shield of Kansas City, and Capital
District Physician’s Health Plan (CDPHP) of New York, all effective
fourth quarter 2022. Biodesix’s Nodify XL2® test will now be
covered for more than 2.3 million enrollees of Blue Cross of North
Carolina, 1.2 million enrollees of Blue Cross Blue Shield of South
Carolina, 0.5 million enrollees from Blue Cross Blue Shield of
Kansas City, and 0.4 million enrollees of CDPHP across New York
State.
“At Biodesix we have a comprehensive suite of five on-market
precision diagnostics to support clinical decision-making across
the lung cancer continuum of care,” said Scott Hutton, Chief
Executive Officer of Biodesix. “While all five of the tests in our
core lung diagnostic testing portfolio are covered by Medicare, we
have been anticipating the first private payer coverage policies.
We were pleased to not only receive our first private payer
coverage, but to receive our first four in rapid succession adding
approximately 4.5 million covered lives. We believe these policies
demonstrate the value payers see in this test and how it can
positively impact patients’ lives.”
The Biodesix Nodify XL2 test is a blood-based proteomic test
designed to help healthcare professionals (HCPs) quickly identify
patients with likely benign lung nodules who may benefit from the
use of computed tomography (CT) surveillance. Clinical validation
studies showed that the test has a 98% negative predictive value,
helping HCPs avoid unnecessary interventional procedures on benign
lung nodules.
Blue Cross Blue Shield Association (BCBSA) consists of 34
independent and locally operated BCBSA companies that provide
health insurance in the United States to one in three Americans
across all 50 states, the District of Columbia and Puerto Rico.
Established in 1984, CDPHP is a physician-founded,
member-focused and community-based not-for-profit health plan that
offers high-quality affordable health insurance plans to members in
29 counties throughout New York.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the NodifyXL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in pulmonary nodules, enabling physicians to
better triage patients to the most appropriate course of action.
The blood based IQLung™ strategy for lung cancer patients
integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an average of 36-72
hours, expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information about
Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221219005228/en/
Media: Robin Harper Cowie robin.cowie@biodesix.com (720)
509-8841
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024